AZD1480, a JAK inhibitor, inhibits cell growth and survival of colorectal cancer via modulating the JAK2/STAT3 signaling pathway

Oncology Reports

Volumn 32, Issue 5, 2014, Pages 1991-1998

  Wang, Shu Wei ^a   Hu, Jun ^a   Guo, Qin Hao ^a   Zhao, Yan ^a   Cheng, Jie Jing ^a   Zhang, Dong Sheng ^a   Fei, Qiang ^a   Li, Juan ^a   Sun, Yue Ming ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

AZD1480; Colorectal cancer; Interleukin 6; Janus kinase 2; Signal transducer and activator of transcription 3; Therapeutic agent

Indexed keywords

5 CHLORO N2 [1 (5 FLUORO 2 PYRIMIDINYL)ETHYL] N4 (5 METHYL 1H PYRAZOL 3 YL) 2,4 PYRIMIDINEDIAMINE; CYCLIN D2; INTERLEUKIN 6; JANUS KINASE 2; STAT3 PROTEIN; IL6 PROTEIN, HUMAN; JAK2 PROTEIN, HUMAN; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE; STAT3 PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CELL PROLIFERATION; COLORECTAL CANCER; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; CYCLIN D2 GENE; DRUG EFFECT; ENZYME INDUCTION; ENZYME PHOSPHORYLATION; GENE TARGETING; HCT116 CELL LINE; HT 29 CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; IL 6 GENE; ONCOGENE C MYC; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; SW480 CELL LINE; ANTAGONISTS AND INHIBITORS; CELL SURVIVAL; COLORECTAL NEOPLASMS; DRUG EFFECTS; METABOLISM; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE;

CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; COLORECTAL NEOPLASMS; HT29 CELLS; HUMANS; INTERLEUKIN-6; JANUS KINASE 2; PHOSPHORYLATION; PYRAZOLES; PYRIMIDINES; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 84907290951     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3477     Document Type: Article

References (38)

1. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin 62: 10-29, 2012.
2. Siegel RL, Ward EM and Jemal A: Trends in colorectal cancer incidence rates in the United States by tumor location and stage, 1992-2008. Cancer Epidemiol Biomarkers Prev 21: 411-416, 2012.
3. Zanders MM, Vissers PA, Haak HR and van de Poll-Franse LV: Colorectal cancer, diabetes and survival: epidemiological insights. Diabetes Metab 40: 120-127, 2014.
4. Jawad N, Direkze N and Leedham SJ: Inflammatory bowel disease and colon cancer. Recent Results Cancer Res 185: 99-115, 2011.
5. Hanahan D and Weinberg RA: Hallmarks of cancer: the next generation. Cell 144: 646-674, 2011.
6. Andersen NN and Jess T: Has the risk of colorectal cancer in inflammatory bowel disease decreased? World J Gastroenterol 19: 7561-7568, 2013.
7. Aggarwal BB, Kunnumakkara AB, Harikumar KB, et al: Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship? Ann NY Acad Sci 1171: 59-76, 2009.
8. Lin Q, Lai R, Chirieac LR, et al: Constitutive activation of JAK3/STAT3 in colon carcinoma tumors and cell lines: inhibition of JAK3/STAT3 signaling induces apoptosis and cell cycle arrest of colon carcinoma cells. Am J Pathol 167: 969-980, 2005.
9. Knüpfer H and Preiss R: Serum interleukin-6 levels in colorectal cancer patients-A summary of published results. Int J Colorectal Dis 25: 135-140, 2010.
10. Morikawa T, Baba Y, Yamauchi M, et al: STAT3 expression, molecular features, inflammation patterns, and prognosis in a database of 724 colorectal cancers. Clin Cancer Res 17: 1452-1462, 2011.
11. Wang SW and Sun YM: The IL-6/JAK/STAT3 pathway: Potential therapeutic strategies in treating colorectal cancer (Review). Int J Oncol 44: 1032-1040, 2014.
12. McFarland BC, Ma JY, Langford CP, et al: Therapeutic potential of AZD1480 for the treatment of human glioblastoma. Mol Cancer Ther 10: 2384-2393, 2011.
13. Scuto A, Krejci P, Popplewell L, et al: The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival. Leukemia 25: 538-550, 2011.
14. Liu Y, Holdbrooks AT, De Sarno P, et al: Therapeutic efficacy of suppressing the Jak/STAT pathway in multiple models of experimental autoimmune encephalomyelitis. J Immunol 192: 59-72, 2014.
15. Murakami T, Takigawa N, Ninomiya T, et al: Effect of AZD1480 in an epidermal growth factor receptor-driven lung cancer model. Lung Cancer 83: 30-36, 2014.
16. Stuart E, Buchert M, Putoczki T, et al: Therapeutic inhibition of jak activity inhibits progression of gastrointestinal tumors in mice. Mol Cancer Ther 13: 468-474, 2014.
17. Yang X, Zhang F, Wang Y, et al: Oroxylin A inhibits colitisassociated carcinogenesis through modulating the IL-6/STAT3 signaling pathway. Inflamm Bowel Dis 19: 1990-2000, 2013.
18. Li GH, Wei H, Lv SQ, Ji H and Wang DL: Knockdown of STAT3 expression by RNAi suppresses growth and induces apoptosis and differentiation in glioblastoma stem cells. Int J Oncol 37: 103-110, 2010.
19. Guthrie GJ, Roxburgh CS, Horgan PG and McMillan DC: Does interleukin-6 link explain the link between tumour necrosis, local and systemic inflammatory responses and outcome in patients with colorectal cancer? Cancer Treat Rev 39: 89-96, 2013.
20. Sakamoto K and Maeda S: Targeting NF-κB for colorectal cancer. Expert Opin Ther Targets 14: 593-601, 2010.
21. Hoesel B and Schmid JA: The complexity of NF-κB signaling in inflammation and cancer. Mol Cancer 12: 86, 2013.
22. Taniguchi K and Karin M: IL-6 and related cytokines as the critical lynchpins between inflammation and cancer. Semin Immunol 26: 54-74, 2014.
23. Putoczki TL, Thiem S, Loving A, et al: Interleukin-11 is the dominant IL-6 family cytokine during gastrointestinal tumorigenesis and can be targeted therapeutically. Cancer Cell 24: 257-271, 2013.
24. Gordziel C, Bratsch J, Moriggl R, Knösel T and Friedrich K: Both STAT1 and STAT3 are favourable prognostic determinants in colorectal carcinoma. Br J Cancer 109: 138-146, 2013.
25. Gu L, Talati P, Vogiatzi P, et al: Pharmacologic suppression of JAK1/2 by JAK1/2 inhibitor AZD1480 potently inhibits IL-6-induced experimental prostate cancer metastases formation. Mol Cancer Ther 13: 1246-1258, 2014.
26. Furqan M, Mukhi N, Lee B and Liu D: Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application. Biomark Res 1: 5, 2013.
27. Lee JH, Park KS, Alberobello AT, et al: The Janus kinases inhibitor AZD1480 attenuates growth of small cell lung cancers in vitro and in vivo. Clin Cancer Res 19: 6777-6786, 2013.
28. Yan S, Li Z and Thiele CJ: Inhibition of STAT3 with orally active JAK inhibitor, AZD1480, decreases tumor growth in neuroblastoma and pediatric sarcomas in vitro and in vivo. Oncotarget 4: 433-445, 2013.
29. Xiong H, Su WY, Liang QC, et al: Inhibition of STAT5 induces G1 cell cycle arrest and reduces tumor cell invasion in human colorectal cancer cells. Lab Invest 89: 717-725, 2009.
30. Xiong H, Zhang ZG, Tian XQ, et al: Inhibition of JAK1, 2/STAT3 signaling induces apoptosis, cell cycle arrest, and reduces tumor cell invasion in colorectal cancer cells. Neoplasia 10: 287-297, 2008.
31. Fletcher S, Drewry JA, Shahani VM, Page BD and Gunning PT: Molecular disruption of oncogenic signal transducer and activator of transcription 3 (STAT3) protein. Biochem Cell Biol 87: 825-833, 2009.
32. Hedvat M, Huszar D, Herrmann A, et al: The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell 16: 487-497, 2009.
33. Reddy MM, Deshpande A and Sattler M: Targeting JAK2 in the therapy of myeloproliferative neoplasms. Expert Opin Ther Targets 16: 313-324, 2012.
34. Tibes R, Bogenberger JM, Geyer HL and Mesa RA: JAK2 inhibitors in the treatment of myeloproliferative neoplasms. Expert Opin Investig Drugs 21: 1755-1774, 2012.
35. Nadiminty N, Lou W, Lee SO, Lin X, Trump DL and Gao AC: Stat3 activation of NF-κB p100 processing involves CBP/p300-mediated acetylation. Proc Natl Acad Sci USA 103: 7264-7269, 2006.
36. Yang J, Liao X, Agarwal MK, Barnes L, Auron PE and Stark GR: Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NFκB. Genes Dev 21: 1396-1408, 2007.
37. Grivennikov S, Karin E, Terzic J, et al: IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-Associated cancer. Cancer Cell 15: 103-113, 2009.
38. Grivennikov S and Karin M: Autocrine IL-6 signaling: a key event in tumorigenesis? Cancer Cell 13: 7-9, 2008.